Application of antigenic peptide EG16 and its antibody in the preparation of diagnostic products for rheumatoid arthritis

CN122080141APending Publication Date: 2026-05-26PEOPLES HOSPITAL PEKING UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
PEOPLES HOSPITAL PEKING UNIV
Filing Date
2026-04-27
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

In the current technology, the early diagnosis of rheumatoid arthritis lacks sensitivity and specificity, especially in the preclinical stage where it is difficult to accurately identify patients and there is a lack of efficient diagnostic methods.

Method used

An ELISA detection kit was prepared using the antigenic peptide EG16, composed of 16 amino acids, and its antibody to detect the epitope antibody content in patient biological samples via ELISA, providing a highly sensitive and specific diagnostic indicator.

Benefits of technology

It significantly improves the diagnostic accuracy of rheumatoid arthritis, especially in the early stages, with a sensitivity of 43.43% and a specificity of 92.80%, providing an efficient auxiliary diagnostic tool for early-stage RA patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122080141A_ABST
    Figure CN122080141A_ABST
Patent Text Reader

Abstract

This invention discloses the application of the antigenic peptide EG16 and its antibody in the preparation of diagnostic products for rheumatoid arthritis (RA), belonging to the field of disease diagnostic technology. This invention aims to address the problem of the lack of highly sensitive and specific serological diagnostic biomarkers for RA (especially early-stage RA). The amino acid sequence of the antigenic peptide EG16 is APKRIRLPHIREDDQP or BSA-C-APKRIRLPHIREDDQP. The RA diagnostic product is used to detect the content of epitope antibodies that specifically bind to the aforementioned antigenic peptide EG16 in patient biological samples. The expression level of this epitope antibody in RA patients is significantly higher than that in healthy individuals and other patients with easily confused rheumatic immune diseases, with a diagnostic sensitivity of 43.43% and a specificity of 92.80%, and a sensitivity of 44.44% in preclinical RA patients. This provides a novel, highly specific auxiliary diagnostic indicator for RA (especially in its early stages).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Citrullinated T200C polypeptide and application of citrullinated T200C polypeptide in preparation of rheumatoid arthritis diagnosis product

    CN121779530A

  • Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis

    US20060141547A1

  • Specific polypeptide related to rheumatoid arthritis and application thereof

    WO2020239090A1